Patents Examined by Laura L. Stockton
  • Patent number: 10323009
    Abstract: The present disclosure provides pharmaceutical compositions comprising Gamma-glutamyl cycle inhibitors (GGCI) and certain pharmaceutically acceptable salts thereof, and methods of use.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: June 18, 2019
    Assignee: CANCER RESEARCH TECHOLOGY, LLP
    Inventors: David Rubin, Eyal Rubin
  • Patent number: 10314820
    Abstract: The present invention relates to novel compounds of formula (I) suitable e.g. as therapeutic agents for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. The present invention also relates to processes for making said agents.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: June 11, 2019
    Assignee: Procomcure Biotech GmbH
    Inventors: Kamil Önder, Roelf Datema, Dale Mitchell, Ivan Kondratov
  • Patent number: 10300048
    Abstract: The invention relates to a compound comprising the following general formula (1) for use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation: (1) wherein each of R1, R2 and R3 are selected independently from each other from alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle or heteroaryl.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: May 28, 2019
    Assignee: UNIVERSITAT BERN
    Inventors: Jean-Louis Reymond, Jurg Gertsch, Simon Nicolussi
  • Patent number: 10301300
    Abstract: Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: May 28, 2019
    Assignee: TEIJIN LIMITED
    Inventors: Takashi Shirakura, Yoshimasa Takahashi, Asahi Kawana, Chikashi Kanazawa
  • Patent number: 10301312
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 28, 2019
    Assignee: Novartis AG
    Inventors: Jiping Fu, Wooseok Han, Subramanian Karur, Peichao Lu, Keith Bruce Pfister, Joseph Michael Young
  • Patent number: 10301256
    Abstract: The present invention provides compounds and pharmaceutical compositions for treating neurological diseases such as multiple sclerosis.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: May 28, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Thomas Andrew Wynn, Christopher P. Hencken
  • Patent number: 10287251
    Abstract: The present invention is to provide a novel pyrazole derivative, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof. The present invention provides a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, which has TRPM8 inhibitory effects: wherein ring A is C6-10 aryl or the like; X is CR4a or the like; R1 and R2 are a hydrogen atom or the like; R3 is a hydrogen atom or the like; R4 is a hydrogen atom or the like; ring B is C6-10 aryl or the like; R5 is a hydrogen atom or the like; R6a is a hydrogen atom or the like; R7a is a hydrogen atom or the like; R7b is a hydrogen atom or the like; R6b is a hydrogen atom or the like; R8 is a hydrogen atom or the like; n is 0, 1 or 2.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: May 14, 2019
    Assignee: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Hideaki Hirasawa, Fumiya Tanada, Yousuke Mutai, Nobuhiko Fushimi, Junichi Kobayashi, Yoshiro Kijima
  • Patent number: 10273248
    Abstract: Provided herein are compounds that modulate glucose uptake activity and are useful for treating cancer, autoimmune diseases, inflammation, infectious diseases, and metabolic diseases. In certain embodiments, the compounds modulate glucose uptake activity by modulating cellular components, including, but not limited to those related to glycolysis and known transporters/co-transporters of glucose such as GLUT1 and other GLUT family members/alternative hexose transporters. In certain embodiments, the compounds have the structure of formula I: Formula (I) wherein the variables have the values disclosed herein.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: April 30, 2019
    Assignee: Kadmon Corportion, LLC
    Inventors: Kellen L. Olszewski, Ji-In Kim, Masha V. Poyurovsky, Kevin G. Liu, Anthony Barsotti, Koi Morris
  • Patent number: 10273217
    Abstract: The present invention relates to compounds of formula I wherein R1? is CH3 R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, hydroxmethyl, or 2-propyl-2-ol; R3 is Cl, F, CF3, cyano, methyl, methoxy, isopropyl, or cyclopropyl; R4 is hydrogen, methyl, F or Cl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: April 30, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Marius Hoener, Juergen Wichmann
  • Patent number: 10271552
    Abstract: The present application relates to thiadiazole compounds, compositions containing such compounds, their use for controlling animal pests including arthropods, insects and nematodes, and to processes and intermediates for the preparation of the thiadiazole compounds.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: April 30, 2019
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Schwarz, Anne Decor, Joerg Greul, Axel Trautwein, Eike Kevin Heilmann, Reiner Fischer, Peter Loesel, Olga Malsam, Daniela Portz, Kerstin Ilg, Herbert Sommer, Sascha Eilmus, Melanie Scharwey, Anton Lishchynskyi, Sven Geibel, Ulrich Goergens, Simon Anthony Herbert, Andreas Turberg
  • Patent number: 10273239
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: April 30, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Patent number: 10266505
    Abstract: The invention describes compounds that inhibit both HDAC and GSK3? (i.e., HDAC/GSK3? dual inhibitors). The invention further describes compositions containing these HDAC/GSK3? dual inhibitors, as well as methods and kits using these HDAC/GSK3? dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3? to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3?. Medical conditions treatable with various embodiments of the invention include but are not limited to cancers and tumors.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: April 23, 2019
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Mouad Edderkaoui, Ramachandran Murali, Stephen Pandol
  • Patent number: 10266539
    Abstract: Polymorphs of a bis-mesylate salt of a compound of Formula I: or a hydrate thereof, are provided. The bis-mesylate salt may also be depicted as a compound of Formula IA: Provided herein are also compositions thereof, methods for their preparation and methods for such polymorphs.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: April 23, 2019
    Assignee: Gilead Connecticut, Inc.
    Inventors: Tim G. Elford, Peter Chee-Chu Fung, Michael Laird Hurrey, Dimitrios Stefanidis, Dragos Vizitiu
  • Patent number: 10265315
    Abstract: Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseases can include cancer, metabolic disorders, human immunodeficiency virus, neurodegenerative disorders, and/or inflammatory diseases. Also provided are methods for regulating SRC family proteins in a cell.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: April 23, 2019
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Bert W. O'Malley, David Michael Lonard, Jin Wang, Jianming Xu, Jianwei Chen
  • Patent number: 10267737
    Abstract: A near-infrared fluorescent probe for detecting ALP is represented by Chemical 1. The fluorescent probe capable of detecting ALP can selectively detect ALP only quickly and accurately. In addition, the fluorescent probe allows monitoring of a biological phenomenon occurring in cells and tissues through noninvasive in-vivo imaging and during the early osteogenic differentiation in real time.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: April 23, 2019
    Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Chang-Soo Lee, Chul Soon Park, Oh Seok Kwon, Tai Hwan Ha
  • Patent number: 10259801
    Abstract: A compound of formula (I) wherein X is O, C?O or S; Y is N or CH; R2 and R4 are each independently H, —(CH2)pCOOH, —(CH2)pCON(R5)2 or —(CH2)pCOOC1-6alkyl; or R2 and R4 together form a 6-membered phenyl ring fused to the five membered ring; each R1 is independently selected from H, halo (e.g. fluoro or chloro), C6-10aryl, C7-12arylalkyl, C2-12 alkenyl; OC1-12 alkyl, OC2-12 alkenyl or a C1-12 alkyl group; each R5 is H or C1-6 alkyl; each p is 0 to 3; n is 1 to 4; or a salt, ester, solvate, N-oxide, or prodrug thereof, e.g. a salt thereof.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: April 16, 2019
    Assignee: Avexxin AS
    Inventors: Berit Johansen, Marcel Sanderberg, Inger-Reidun Aukrust, George Kokotos, Efrosini Barbayianni
  • Patent number: 10259795
    Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as pre-term labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: April 16, 2019
    Assignee: Merck Serono S.A.
    Inventors: Patrick Naxos Page, Matthias Schwarz, Catherine Jorand-Lebrun, Anna Quattropani, Vincent Pomel
  • Patent number: 10253032
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: April 9, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Patent number: 10246427
    Abstract: 1,2,3-triazolyl cyclohexanol derivatives have been disclosed and their use as ligands accelerating the copper(I)-catalyzed azide-alkyne cycloaddition and the zinc(II)-catalyzed azide-nitrile cycloaddition.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: April 2, 2019
    Assignee: UNIWERSYTET JAGIELLONSKI
    Inventors: Przemyslaw Szafranski, Patryk Kasza, Marek Cegla
  • Patent number: 10243150
    Abstract: A compound of the general formula (I), a process for the production of the compound and its use in electronic devices, especially electroluminescent devices. Improved efficiency, stability, manufacturability, or spectral characteristics of electroluminescent devices are provided when the compound of formula I is used as host material for phosphorescent emitters in electroluminescent devices.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: March 26, 2019
    Assignee: UDC IRELAND LIMITED
    Inventors: Thomas Schaefer, Flavio Luiz Benedito, Ute Heinemeyer, Nicolle Langer, Heinz Wolleb, Teresa Marina Figueira Duarte, Soichi Watanabe, Christian Lennartz, Gerhard Wagenblast, Annemarie Wolleb, Kristina Bardon